Recent legal changes, introduced by EA PO, allows to include national patents in the EA pharmaceutical registry (active from March 2021); however, not every member country is yet willing to submit actual information on its patents. Therefore, national registries of pharmaceutical patents are still necessary.
Russian registry is still in its prototype stage and it is expected that legal framework shall be finished soon. Yury Zubov, head of RU PTO, recently stressed a necessity of parallel registry, deriving from experience, already available in EAPO. The head of the latter, Grigory Ivliev, confirmed the EA legal base is ready and theoretically every claimant may add a national patent to EA registry. But not all national PTOs are willing to provide restricted information on the patents, so the registry is doomed to be incomplete till then.
Russia is updating its intellectual property legislation to reflect the way modern digital technologies are…
Patentica is proud to announce that our Eurasian patent attorneys, Ekaterina Petrova and Victor Lisovenko,…
AstraZeneca has registered Baxfendi (baxdrostat) in Russia for the treatment of arterial hypertension. The medicine…
On July 10, 2026, the Eurasian Patent Organization (EAPO) acceded to the Geneva Act of…
Rospatent and Indonesia's Ministry of Law have signed a Memorandum of Understanding (MoU) to expand…
In 2026, the Eurasian industrial design system marks its fifth anniversary. Over the past five…